Syntekabio Raises 2 Billion Won in Rights Offering—The Real Purpose Behind Securing Operating Funds

Syntekabio’s board of directors resolved on the 31st to issue 1,566,170 common shares at 1,277 won per share through a third-party allotment rights offering. The financing will raise approximately 2 billion won, all of which will be allocated to operating funds. Payment is due on the 8th of next month, the new shares are scheduled to be listed on the 22nd of the same month, and the subscription date is the 4th of next month.

The issue price was calculated by applying a 10% discount to the reference price of 1,418 won, the weighted arithmetic average share price from the third to fifth trading days before the subscription date. The new shares will be allocated equally, with 783,085 shares each going to Lee Jeong-hun and the Syntekavalueup Investment Association.

The offering will be conducted as a small-scale public offering, with the amount raised below 3 billion won, exempting the company from filing a securities registration statement. The company plans to file a corrected disclosure once the issue price is finalized based on the subscription date.

Competition in the global AI drug discovery platform market accelerates

On the surface, the offering is simply intended to raise operating funds, but its strategic context becomes clearer when examining where the money will go. Syntekabio is conducting global collaborative research with U.S. clinical-stage biotech company MetaVia and Ukrainian compound library company Enamine. In its collaboration with MetaVia, the company is conducting AI virtual screening against more than 1,700 protein targets, while its partnership with Enamine integrates a large-scale compound library with its proprietary AI platform.

The company’s core competitive advantages are the AI Bio Supercomputing (ABS) Center in Daejeon and its proprietary AI platform, DeepMatcher. Using language model-based virtual screening technology, DeepMatcher can screen more than 10 billion compounds in just 2 hours. Its ability to significantly shorten the early drug candidate discovery process, which traditionally took years, has drawn the attention of global pharmaceutical companies.

Sustainability of the “develop now, pay later” model is key

Syntekabio has introduced its “Develop Now, Pay Later (DNPL)” model to overseas markets, conducting AI drug development without upfront costs and sharing revenue upon success. Although the model lowers the barriers to entry for customers and is advantageous for securing overseas partnerships, it also means the company must cover the upfront costs itself. The 2 billion won rights offering appears to be largely intended to meet this structural funding requirement.

Industry views are divided over the sustainability of the DNPL model itself. Some observers point out that unless a license-out deal with a global big pharma company or a large-scale collaborative research agreement becomes visible, the company may continue to repeatedly raise operating funds through small-scale public offerings. In addition to its small-molecule synthetic drug platform, DeepMatcher, Syntekabio is expanding the application of its AI platforms into personalized cancer vaccines (NEO-ARS) and antibody drugs (Ab-ARS), making the timing of monetization through pipeline diversification a key variable.

Meanwhile, the global AI drug development market is projected to grow at an annual average rate of 28.1%, from approximately $5.09 billion in 2026 to $17.56 billion in 2031. Syntekabio plans to demonstrate its technology and pursue partnerships through major global biotech events, including BIO-Europe 2025 (Milan) and BIO USA 2025 (Boston), suggesting that a significant portion of the funds raised will be spent on overseas marketing.